Aducanumab Virtual Symposium at Johns Hopkins University

Description

Join moderator Dan Gorenstein, executive producer and host of Tradeoffs, and panelists for a seminar titled "FDA approves $56,000 treatment for Alzheimer's with Questionable Efficacy – What Happens Next?," presented by the Hopkins Business of Health Initiative (HBHI) and the Hopkins Economics of Alzheimer's Disease and Services Center (HEADS Center).

Panel 1 at 9 a.m.: "Accelerated approval of Aducanumab by FDA – scientific justification and implications of approval for patients"

• Caleb Alexander, professor of epidemiology, Johns Hopkins University
• Marwan Noel Sabbagh, director of translational research, Cleveland Clinic Lou Ruvo Center for Brain Health
• Holly Fernandez Lynch, assistant professor of medical ethics and assistant professor of law, University of Pennsylvania

Panel 2 at 10 a.m.: "Market access to aducanumab – the clinical issues and dilemmas"

• Halima Amjad, assistant professor of medicine, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine
• Patient (TBD)
• Alice Bonner, director of strategic partnerships for CAPABLE, Johns Hopkins University; former secretary of the Executive Office of Elder Affairs for the Commonwealth of Massachusetts

Panel 3 at 11 a.m.: "Who pays and how – consideration of options for Medicare"

• Tricia Neuman, senior vice president, Kaiser Family Foundation; executive director of program on Medicare Policy
• Sean Tunis, senior fellow, Center for Evaluation of Value and Risk in Health, Tufts Medical Center; mentor-in-residence, Johns Hopkins Tech Ventures
• Howard Fillit, founding executive director and chief science officer, The Alzheimer's Drug Discovery Foundation; clinical professor of geriatric medicine, palliative care and neuroscience, The Icahn School of Medicine at Mount Sinai

Closing remarks by Joshua Sharfstein, vice dean for public health practice and community engagement, and professor of the practice, Bloomberg School of Public Health.